Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Cerus Corp Market Cap
The Cerus Corp (CERS) share price is expected to increase by 111.59% over the next year. This is based on calculating the average 12-month share price estimate provided by 3 stock analysts who have covered CERS. Price targets range from $2.5 at the low end to $6 at the high end. The current analyst consensus for CERS is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 3 Wall Street analysts have assigned CERS 3 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Cerus Corp to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on CERS. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of CERS.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Ross Osborn Cantor Fitzgerald | Overweight | $4 | Maintains | May 3, 2024 |
Craig-Hallum | Buy | $5 | Initiates | Apr 12, 2024 |
| Jacob Johnson Stephens & Co. | Equal-Weight | $2.5 | Reiterates | Mar 7, 2024 |
| Ross Osborn Cantor Fitzgerald | Overweight | $3 | Reiterates | Mar 6, 2024 |
| Ross Osborn Cantor Fitzgerald | Overweight | $3 | Assumes | Nov 8, 2023 |
| Mark Massaro BTIG | Neutral | Downgrade | Jan 20, 2023 | |
Stifel | Buy | $8 | Maintains | May 27, 2020 |
| Jacob Johnson Stephens & Co. | Overweight | $6.5 | Maintains | Apr 16, 2020 |
BTIG | Buy | Initiates | Feb 26, 2020 | |
BTIG Research | Buy | Initiates | Feb 26, 2020 | |
BTIG Research | Buy | Upgrade | Nov 13, 2019 | |
BTIG | Buy | Upgrade | Nov 13, 2019 | |
Stifel | Buy | Initiates | Aug 28, 2019 | |
BTIG Research | Buy | Maintains | Apr 22, 2016 | |
BTIG | Buy | $10 | Maintains | Apr 22, 2016 |
Wedbush | Neutral | Downgrade | Dec 17, 2015 | |
BTIG Research | Buy | Initiates | Apr 24, 2015 | |
BTIG | Buy | Initiates | Apr 24, 2015 | |
Cantor Fitzgerald | Buy | $7 | Maintains | Feb 27, 2015 |
MLV & Co. | Buy | $7 | Maintains | Dec 2, 2014 |
When did it IPO
1997
Staff Count
625
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Mr. William M. Greenman
Market Cap
$429.9M
In 2023, CERS generated $156.4M in revenue, which was a decrease of -3.51% from the previous year. This can be seen as a signal that CERS's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 01 Aug 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Cerus Corporation (NASDAQ:CERS ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Jessica Hanover - VP, Corporate Affairs Obi Greenman - President & CEO Vivek Jayaraman - COO Kevin Green - CFO Conference Call Participants Ross Osborne - Cantor Fitzgerald Jacob Johnson - Stephens Eric Anderson - TD Cowen Vidyun Bais - BTIG William Bonello - Craig-Hallum Capital Group Operator Good day, ladies and gentlemen. Thank you for standing by, and welcome to the Cerus Corporation Second Quarter 2024 Earnings Conference Call.
Thu, 01 Aug 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for its second quarter and six months ended June 30, 2024. Total revenue for the three and six months ended June 30, 2024 was comprised of (in thousands, except %): Three Months Ended Six Months Ended June 30, Change June 30, Change 2024 2023 $ % 2024 2023 $ % Product Revenue $ 45,079 $ 38,853 $ 6,226 16 % $ 83,444 $ 69,827 $ 13,617 20 % Government Contract Revenue 5,440 8,875 (3,435.
Thu, 01 Aug 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Cerus (CERS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.07 per share a year ago.
Thu, 18 Jul 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2024 financial results will be released on Thursday, August 1, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the.
Tue, 02 Jul 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced the appointment of Dean Gregory to its Board of Directors. Mr. Gregory has a 30+-year career as a leader in the global blood transfusion and cell therapy industry, with broad experience across commercialization, product development, supply chain and manufacturing. For the last decade, Mr. Gregory served as President, Global Commercial Operations, Med Tech for Fresenius Kabi, the role from which he retired earlier.
Fri, 21 Jun 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) today announced a lunch symposium and selection of abstracts at the 38th International Congress of the International Society of Blood Transfusion (ISBT), taking place in Barcelona, Spain, from June 23 through June 27. Transfusion medicine experts and professionals from around the world attend the ISBT Congress. The following is a list of selected presentations and abstracts of interest for Cerus. All presentation times are listed.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
